Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 24, 2018 09:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis

-- SNA-120, a new chemical entity derived from the company’s Topical by Design™ platform, was well tolerated with minimal to no detectable systemic exposure -- Vast majority of psoriasis patients...